Drugs / TPIP F3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07102316 | Aug → Oct 2025 | — | Insmed Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPIP F3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07102316 ↗ |
| Route | Inhaled | “Inhalation using a capsule-based dry powder inhaler device.” NCT07102316 ↗ |